Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: dicerna.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $28.00 → $38.25 | Buy → Neutral | Chardan Capital |
| 11/19/2021 | $30.00 → $38.25 | Outperform → Sector Perform | RBC Capital |
| 11/18/2021 | $32.00 → $38.25 | Buy → Neutral | HC Wainwright & Co. |
| 8/11/2021 | $36.00 → $25.00 | Buy → Neutral | Goldman Sachs |
| 8/10/2021 | $34.00 → $28.00 | Buy | Chardan Capital |
| 8/10/2021 | $38.00 → $32.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $32.00 | Buy → Neutral | Citigroup |
| 8/6/2021 | $35.00 → $30.00 | Outperform | RBC Capital |
| 8/6/2021 | $48.00 → $36.00 | Buy | Goldman Sachs |
| 8/6/2021 | $54.00 → $47.00 | Outperform | SVB Leerink |
SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
– Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communications – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard, Esq., to Dicerna's executive leadership team as Senior Vice President, Investor Rela
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new employees with a grant date of Jan. 4, 2021 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $22.07
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,
Chardan Capital downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $28.00 previously
RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously
HC Wainwright & Co. downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $32.00 previously
Goldman Sachs downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $25.00 from $36.00 previously
Chardan Capital reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $28.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $38.00 previously
Citigroup downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $32.00
RBC Capital reiterated coverage of Dicerna Pharmaceuticals with a rating of Outperform and set a new price target of $30.00 from $35.00 previously
Goldman Sachs reiterated coverage of Dicerna Pharmaceuticals with a rating of Buy and set a new price target of $36.00 from $48.00 previously
SVB Leerink reiterated coverage of Dicerna Pharmaceuticals with a rating of Outperform and set a new price target of $47.00 from $54.00 previously
15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
POSASR - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,
– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4
– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria – – Announced U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for DCR-AUD for Alcohol Use Disorder – – Announced Interim Phase 1 Results and Initiated Patient Dosing in ESTRELLA Phase 2 Study of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (AATLD) – – Received $10.0 Million Milestone Payment Following FDA Acceptance of Lilly's Second GalXC RNAi IND Application Under Companies' Global Research Collaboration and Licensing Agreement – – Company
– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants – – Nedosiran Was Generally Well Tolerated in PHYOX2 With a Safety Profile Similar to Previously Reported PHYOX Trial Results – – Results Further Validate GalXC™ RNAi Technology Platform and its Ability to Silence Disease-Driving Genes – – Management to Host Conference Call and Webcast Today at 4:30 p.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutic
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021. Management will host a conference call at 8:00 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharma
LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (“Alnylam”). “We are very pleased to have entered into this agreement with Royalty Pharma, which is r
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any withholding of taxes. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Other conditions remain to be satisfied, inclu
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR). MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology. The MSGR ETF seeks investment results, before fees and expenses, of the BITA Messenger RNA Technology Index. The BITA Messenger RNA Technology Index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of mRNA technology. mRNA is a single-stranded ribonucleic acid molecule that is complementary to one of the DNA strands of a gene. mRNA plays a vital role i
– Acquisition to Accelerate and Expand Novo Nordisk Development of RNAi Therapeutics Using Dicerna's Proprietary GalXC™ Technology Platform – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. The transaction was unanimously approved by the Dicerna Board of Directors and the Board of Directors of
– Milestone Triggers Two Single-Digit Multimillion-Dollar Payments to Dicerna – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company ("Lilly") has declared proof of principle for the first two targets in the companies' exclusive relationship in neurodegeneration and pain, under the companies' global research and licensing collaboration. This milestone triggers two single-digit multimillion-dollar milestone payments to Dicerna, which the Company expects to receive in the fourth quarter of 2021. "We are very pleased to announce Lilly's selection of two extrahepatic ta
– Belcesiran Was Shown to Be Safe and Well Tolerated in Phase 1 Trial and Demonstrated Robust, Dose-Dependent Reductions in Serum Alpha-1 Antitrypsin – – Enrollment in ESTRELLA Phase 2 Study of Belcesiran Is Ongoing; Global Rollout to Additional Trial Sites Continues – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). These data expand upon interim res
– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a
– Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare Utilization Data Showed Delayed Diagnosis in More Than 50% of Patients, High Rates of Healthcare Use and Substantial Costs Following Start of Dialysis – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced results of the PHYOX™2 pivotal clinical trial of nedosiran, an investigational GalXC™ RNAi candidate for the treatment of primary hyperoxaluria (PH), in a late-breaker poster presentation at the American S
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4
SVB Leerink boosted the price target on Edwards Lifesciences Corporation (NYSE:EW) from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday. Keybanc raised The Sherwin-Williams Company (NYSE:SHW) price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday. Piper Sandler cut Udemy, Inc. (NASDAQ:UDMY) price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday. Needham lowered the price target on Esperion Therapeutics, Inc. (NASDAQ:ESPR) from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday. JP Morgan lifted Phillips 66 (NYSE:PSX) price target from $83 to $93. Phillips 66 shar
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform. BMO Capital upgraded the previous rating for Nuvei Corp (NASDAQ:NVEI) from Market Perform to Outperform. For Cadence Bank (NYSE:CADE), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. Cadence Bank earned $0.67 in the third quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.12 and a 52-week-low of $14.47. Cadence Bank closed at $29.39 at the end of the last trading period. According to Raymond James, the prior rating for Boyd Gaming Corp (NYSE:BYD) was changed from Outperform to Strong
Chardan Capital analyst Keay Nakae downgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) from Buy to Neutral and raises the price target from $28 to $38.25.